FAQ • Attendee Wellbeing • Make an Impact • Register (In-Person or Virtual!) • Schedule • Posters • Resources • Engage/Mentoring • Students • Hotel/Travel • Supporters

Clinical Pearls 1

Registration Options

Activity Date: 04/09/2024

AAPP 2024 registration is closed.

Session Time and Location

The live session is complete.

Target Audience

If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.

Session Summary

Clinical Pearls presentations will be recorded and posted but are only available for live credit.

Paternal Postpartum Depression - Identification and Barriers
Shari N. Allen, PharmD, BCPP

1 in 8 mothers will experience postpartum depression (PPD). In women, PPD, is commonly screened for and recognized. The incidence in male partners ranges from 8-13% but largely goes under studied, under assessed, and under treated. The higher risk in men may correlate with PPD in the birth parent as well as previous episodes of depression. While the treatment of PPD in men and women is similar, the clinical presentation in men is more associated with irritability, emotional bluntness, and indecisiveness. Men may present with resistance to seeking help and accepting treatment. It is important to identify and address paternal postpartum depression because a lack of doing so may result in negative outcomes for the child and the family unit.


Tackling the Treatment of Tardive Dyskinesia
Ahmaya Mustafa, PharmD, BCPS

Tardive dyskinesia is a condition which can affect many patients receiving long-term antipsychotic treatment. The management of tardive dyskinesia has undergone significant advancements since the publication of the American Academy of Neurology guidelines in 2013. This presentation aims to provide insights into the management of tardive dyskinesia using vesicular monoamine transporter 2 (VMAT-2) inhibitors, while also discussing alternative treatment strategies for patients who are unable to use this class of medications.


Home Sweet Home: Operationalizing Low-Dose Buprenorphine Initiations for Virtual Care
Audrey Abelleira, PharmD, BCPS, BCPP

Buprenorphine utilization is increasing as its role in chronic pain management expands and access increases due to elimination of the X-waiver. In the post-COVID landscape more patients and providers are relying on telehealth to provide needed care to under-resourced or rural communities. The traditional method for initiating buprenorphine may present a barrier to treatment for these patients due to fear of experiencing opioid withdrawal or inability to travel to the clinic due to rurality or reliance on telehealth to receive chronic pain and opioid use disorder care. Low-dose buprenorphine initiations (LDBI) represent an alternative to traditional initiations; buprenorphine's affinity for the mu receptor is used strategically to gradually introduce a therapeutic dose of buprenorphine over several days, allowing for a discontinuation of full agonists with minimal opioid withdrawal symptoms while completing the process from home. Many questions remain regarding not only home initiations of buprenorphine, but also LDBI, and how best to incorporate this into clinical practice.

 

Consider making this session part of your BPS Continuing Professional Development plan! Please refer to the BPS Psychiatric Pharmacy Content Outline to see how this activity may align.

Course Requirements

To receive ACPE credit for the live session at the Annual Meeting, you must:

  • Sign in (or create a FREE account).
  • Register for this course.
  • Attend and participate in the entire session and reflect upon its teachings.
  • Complete the evaluation at the end of the activity.
  • Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.

Upon successful completion, ACPE credit is reported within 24 hours to CPE Monitor although transcripts can be retrieved by participants online in their ACPE Transcript.

Faculty Information and Disclosures

Shari N. Allen, PharmD, BCPP
Ahmaya Mustafa, PharmD, BCPS, BCPP
Audrey Abelleira, PharmD, BCPS, BCPP

View biographical information and disclosures

Learning Objectives

Paternal Postpartum Depression - Identification and Barriers

  1. Identify the signs and symptoms of postpartum depression in paternal partners.
  2. Recognize barriers to recognizing paternal postpartum depression and the outcomes of delayed identification.

Tackling the Treatment of Tardive Dyskinesia

  1. Identify factors which impact Vesicular Monoamine Transporter 2 (VMAT-2) inhibitor selection and use.
  2. Develop a pharmacologic treatment plan for the management of tardive dyskinesia.

Home Sweet Home: Operationalizing Low-Dose Buprenorphine Initiations for Virtual Care

  1. Differentiate between buprenorphine initiation methods and determine when a low-dose initiation may be appropriate
  2. Review logistical considerations involved in formulating a low-dose buprenorphine initiation transition plan implemented through telehealth.

Continuing Education Credit and Disclosures

Activity Date: 04/09/2024
ACPE Contact Hours: 1
ACPE Number: 0284-0000-24-031-L04-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.